1. A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC)
    Pedro Barata et al, 2018, Invest New Drugs CrossRef
  2. Therapeutic Targeting of the IGF Axis.
    Eliot Osher et al, 2019, Cells CrossRef
  3. In search for geroprotectors: in silico screening and in vitro validation of signalome-level mimetics of young healthy state
    Alexander Aliper et al, 2016, Aging CrossRef
  4. Pharmacological Small Molecules against Prostate Cancer by Enhancing Function of Death Receptor 5
    Xia Gan et al, 2022, Pharmaceuticals CrossRef
  5. Mini Review: Molecular Interpretation of the IGF/IGF-1R Axis in Cancer Treatment and Stem Cells-Based Therapy in Regenerative Medicine
    Syuan-Ling Lin et al, 2022, IJMS CrossRef
  6. Small-Molecule Protein Tyrosine Kinase Inhibitors for the Treatment of Metastatic Prostate Cancer
    Gary E Gallick et al, 2012, Future Med. Chem. CrossRef
  7. null
    Sandipan Das et al, 2024 CrossRef